SHARE
During a time where health is globally prioritized more than ever due to the COVID-19 pandemic, learning about investment in open innovation has become an important part of accessible health care. Vaccines, therapies, diagnostics and treatment regimens are now able to be developed quicker than ever with the proper incentives and resources. Kathleen Entwistle, private wealth advisor at Morgan Stanley Private Wealth Management, Paul Fehlner, cofounder and president/CEO of reVision Therapeutics, Inc., and Barbara Handelin, cofounder and CEO of Audacity Therapeutics, PBC, recently discussed with
Worth how medicine is changing the future of health care.
According to Handelin, Audacity Therapeutics’ main focus is to develop “as many medicines as we could for important, serious diseases using all kinds of innovation, including, and especially, the repurposing of existing drugs, and investing in the kinds of diagnostics that just will never be touched by venture capital.” However, when it comes to COVID-19 and in general, there have been no incentives to do that financially.